scholarly journals Patient Assistance Programs and Technology in Medication Adherence

2020 ◽  
Vol 11 (2) ◽  
pp. 9
Author(s):  
Carlos Colon ◽  
Raiza Cotto ◽  
Militza Diaz ◽  
Isabel Martinez ◽  
Paulette Salas ◽  
...  
Keyword(s):  
Medication Adherence ◽  
Medication Management ◽  
Assistance Program ◽  
Assistance Programs ◽  
Disease States ◽  
Lower Education Level ◽  
Patient Assistance ◽  
Quasi Experimental ◽  
Care Assistance ◽  
The Impact

Background: Patient assistance programs, including medication management and counseling, have the potential to improve care in chronic disease states with complex therapies. Incorporating technology as a tool to foster adherence is becoming more commonplace in practice. Objectives:  The purpose of this report is to identify barriers of medication adherence and review the impact of patient assistance programs and technology on medication adherence. Methods: A literature search was conducted in secondary databases, PubMed/MEDLINE and EBSCOhost of peer-reviewed systematic reviews, experimental, quasi-experimental, and observational reports published in English within the last fifteen years. Terms searched included patient assistance program, pharmacist role, technology, adherence or compliance, income and health. Results: Ten studies met our prespecified criteria. Male sex, several self-reported chronic diseases, negative expectancy of treatment, engagement in polypharmacy, financial hardships and lower education level correlated with lower medication adherence. Patient care assistance programs and utilization of technology (e.g., use of a mobile application) improved medication adherence. Conclusions: Patient assistance programs and technological tools, such as mobile applications, are necessary resources in improving medication adherence.   Article Type: Idea Paper

scholarly journals Transparency of Industry-Sponsored Oncology Patient Financial Assistance Programs Using a Patient-Centered Approach

2017 ◽  
Vol 13 (3) ◽  
pp. e240-e248 ◽  
Author(s):  
S. Yousuf Zafar ◽  
Jeffrey Peppercorn ◽  
Akwasi Asabere ◽  
Alex Bastian
Keyword(s):  
Web Sites ◽  
Free Drug ◽  
Financial Assistance ◽  
Oncology Patient ◽  
Assistance Program ◽  
Specific Patient ◽  
Assistance Programs ◽  
Average Maximum ◽  
Patient Assistance ◽  
The Impact

Objective: Pharmaceutical manufacturers sponsor drug-specific patient assistance programs that provide eligible patients with financial assistance, either in the form of providing the drug free of charge or copayment assistance. Describing these programs and determining who receives assistance is an important first step in understanding the impact and role of financial assistance in cancer care. Our objective was to describe eligibility criteria and benefits for cancer-specific, manufacturer-sponsored patient assistance programs. Methods: We conducted a prospective review of patient assistance program Web sites and called patient assistance program telephone hotlines from the perspective of a patient or caregiver requesting program details. Results: We identified 24 manufacturers with patient assistance programs, covering 87% of Food and Drug Administration–approved oncology drugs. For free drug programs, the average maximum annual income for qualification was $86,279. For copayment assistance programs, the average was $104,790. Thirty-five percent of free drug programs and 53% of copayment assistance programs declined to provide details on how financial need was determined. None of the programs shared details on patient usage statistics. Conclusion: Variation exists in the quality and quantity of data available to patients seeking financial assistance for cancer treatment via manufacturer Web sites and hotlines. Greater transparency among patient assistance programs would enhance utility for patients and help to determine the net impact on costs and adherence.

Cardiovascular Risk Reduction in the Workplace With CAMMPUS (Cardiovascular Assessment and Medication Management by Pharmacists at the UBC Site)

2019 ◽  
Vol 53 (6) ◽  
pp. 574-580 ◽  
Author(s):  
Barbara Gobis ◽  
Anita I. Kapanen ◽  
Jillian Reardon ◽  
Jason Min ◽  
Kathy H. Li ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Medication Adherence ◽  
Risk Reduction ◽  
Medication Management ◽  
Baseline Assessment ◽  
Cardiovascular Risk Reduction ◽  
Cardiovascular Assessment ◽  
Preventive Health Programs ◽  
The Impact

Background: Cardiovascular (CV) disease is a leading cause of death despite being largely preventable. Employers increasingly offer preventive health programs in the workplace, and pharmacists are well suited to provide these programs. Objective: To evaluate the impact of a pharmacist-led service on CV risk in University of British Columbia (UBC) employees. Methods: This was a prospective observational pre-and-post design study, with participants as their own controls. Employees >18 years of age in the UBC health plan with a Framingham Risk Score (FRS) ≥10% or ≥1 medication-modifiable CV risk factor were included. Participants received a baseline assessment, individualized consultation for 12 months, and a final assessment by a pharmacist at the UBC Pharmacists Clinic. The primary end point was FRS reduction. Results: Baseline assessment of 512 participants between September 2015 and October 2016 yielded 207 (40%) participants, of whom 178 (86%) completed the 12-month intervention. Participants were 54% female and 55% Caucasian, with an average age of 51 (SD = 9.1) years. FRS at baseline was <10 in 45.8%, 10 to 19.9 in 37.9%, and ≥20 in 16.4% of participants. Over 12 months, significant reductions in average FRS (from 11.7 [SD = 7.7] to 10.7 [SD = 7.3]; P = 0.0017) and other parameters were observed. Significant improvements in quality of life (EQ5D change of 0.031 [95% CI = 0.001, 0.062] P = 0.023) and medication adherence (MMAS-8 change of 0.42 [ P = 0.019]) were also noted. Conclusions and Relevance: UBC employees had improvements in health markers, self-reported quality of life, and medication adherence after receiving a 12-month pharmacist-led intervention. Pharmacists are encouraged to provide CV risk reduction services in workplaces.

scholarly journals Utilization of Pharmaceutical Patient and Prescription Assistance Programs via a Pharmacy Department Patient Assistance Program for Indigent Cancer Patients

2016 ◽  
Vol 51 (7) ◽  
pp. 572-576 ◽  
Author(s):  
Limin Gao ◽  
Jivin Joseph ◽  
Marcelle Santoro-Levy ◽  
Alan S. Multz ◽  
Vladimir K. Gotlieb
Keyword(s):  
Cancer Patients ◽  
Assistance Program ◽  
Assistance Programs ◽  
Pharmacy Department ◽  
Patient Assistance

scholarly journals STUDI KASUS INTERVENSI PEMERINTAH BAGI USAHA MIKRO, KECIL, DAN MENENGAH DI MASA PANDEMI COVID-19

2021 ◽  
Vol 6 (3) ◽  
pp. 263-287
Author(s):  
Marwanto Harjowiryono ◽  
Windraty Ariane Siallagan
Keyword(s):  
Financial Literacy ◽  
Success Factors ◽  
Government Programs ◽  
Assistance Program ◽  
Assistance Programs ◽  
Key Success Factors ◽  
The Future ◽  
The Government ◽  
The Impact

This study investigates the impact of the COVID-19 pandemic on MSMEs and how Government intervention affects their capacity to survive. Through a survey of 368 respondents, namely debtors/beneficiaries, aid distributors, policymakers, and supervisors, this case study finds that the COVID-19 pandemic has resulted in business delays. The finding means that the government assistance schemes are the key to business continuity for MSMEs during the COVID-19 pandemic. With the help from the Government, the business actors in the sample of this study can maintain their business. Although some MSMEs reduced the number of workers employed, some MSMEs still survived, even increased their workers and business turnover. While the research identifies key success factors of Government programs, there are also some challenges in their implementation. This study recommends that the Government continues giving assistance programs for MSMEs. In addition, the Government should relax requirements while focusing on new beneficiaries. Building an integrated MSME database is also necessary, and in the future, the Government must integrate the assistance program with financial literacy and innovation programs. The policy implication of this research is that the future programs of government poverty alleviation need to focus on MSMEs.

scholarly journals Comparison of Emergency Preparedness Practices between Food Assistance Program Participants and Non-Participants in the United States

2021 ◽  
Vol 18 (24) ◽  
pp. 12937
Author(s):  
Gina J. Fung ◽  
Laura K. Jefferies ◽  
Michelle A. Lloyd Call ◽  
Dennis L. Eggett ◽  
Rickelle Richards
Keyword(s):  
United States ◽  
Low Income ◽  
Emergency Preparedness ◽  
The United States ◽  
Food Assistance ◽  
Food Assistance Programs ◽  
Assistance Program ◽  
Convenience Sample ◽  
Assistance Programs ◽  
The Impact

Background: Previous research has suggested many households are meeting the Federal Emergency Management Agency’s 3-day emergency food and water storage recommendations. The impact of limited economic household resources on emergency preparedness practices related to food and water is uncertain. The purpose of this study was to compare emergency preparedness practices in households participating in United States’ food assistance programs with households not participating in these programs. Methods: A convenience sample of adults (n = 572) completed an online Qualtrics survey. Descriptive statistics, chi-square statistics, and independent t-tests were used to measure differences between households participating in food assistance programs vs. non-participating households. Results: Most households participating in food assistance programs felt prepared to provide household members with food and water during an emergency, which did not significantly differ from non-participating households. Households using food assistance programs had less accessible cash but had similar foods on-hand for an emergency compared to non-participating households. However, they more frequently reported having baby formula/food and less frequently reported having vitamin/mineral supplements compared to non-participating households. Conclusions: Food assistance programs may be effective in providing enough food and water to help low-income families be prepared for an emergency.

Impact of Oral Chemotherapy Management Program on Capecitabine Toxicity Management

2021 ◽  
pp. OP.20.00947
Author(s):  
Salin Nhean ◽  
Diana Kostoff ◽  
Jessica J. Yang ◽  
Vishnuprabha Vogel ◽  
Igor I. Rybkin
Keyword(s):  
Medication Adherence ◽  
Management Program ◽  
Oral Chemotherapy ◽  
Adherence Rate ◽  
Before And After ◽  
Henry Ford ◽  
Quasi Experimental ◽  
Ed Visits ◽  
Grade 3 ◽  
The Impact

PURPOSE: Increasing use of oral chemotherapy has created unique challenges related to patient safety and compliance. To address this issue, the Henry Ford Cancer Institute at Henry Ford Health System developed and implemented a system-wide, multidisciplinary program named the Oral Chemotherapy Management Program (OCMP). The purpose of this study was to evaluate the impact of OCMP on patient outcomes in those receiving capecitabine. METHODS: This was a retrospective, quasi-experimental study that compared outcomes in patients receiving capecitabine before and after OCMP implementation. The co-primary outcomes were incidence(s) of grade 1-4 and grade 3-4 adverse effects (AEs) associated with capecitabine. Secondary outcomes were emergency department (ED) visits, hospitalizations because of toxicity, and adherence rate. RESULTS: OCMP patients had significantly lower overall incidence of AE of any grade (58.9% v 70.3%; 95% CI, 0.39 to 0.94; P = .03). OCMP implementation significantly lowered incidence of any grade and grade 3-4 nausea, vomiting, and/or diarrhea, and grade 3-4 hand-foot syndrome. It resulted in the decreased number of ED visits (8.9% v 18.9%; P = .005) and hospitalizations (6.3% v 17.1%; P = .002), as well as improved medication adherence rates (0.94 v 0.97; P = .03). CONCLUSION: Most patients who developed capecitabine-related AE required intervention by OCMP. Implementation of OCMP reduced the incidence of high-grade AE, decreased the number of ED visits and hospitalizations because of AE, and improved the medication adherence rate.

U.S. Military Assistance to Latin America: An Assessment

1972 ◽  
Vol 14 (4) ◽  
pp. 469-488 ◽  
Author(s):  
John M. Baines
Keyword(s):  
Latin America ◽  
List Type ◽  
Type Number ◽  
Military Assistance ◽  
Assistance Program ◽  
Internal Security ◽  
Assistance Programs ◽  
Military Regimes ◽  
The Military ◽  
The Impact

This paper examines the nature of the U.S. Military Assistance Program (MAP) to Latin America and the historical development of the Military Assistance Program in the hemisphere. It further analyzes this program with regard to the two major criticisms levelled at it:(1)that Military Assistance Programs have perpetuated “militarism” in the form of military coups and strong-man military regimes; and(2)that Military Assistance Programs have encouraged large military forces where they are not needed.Changes in U.S. policy toward Latin America are noted as they affect MAP—i.e., the shift in U.S. policy from one of fostering hemispheric defense to one of promoting internal security and economic development. Finally, an assessment of the impact of this change in U.S. military assistance policy forms the conclusion of this paper.

Development of a systematic approach to pharmaceutical industry’s patient assistance programs on accessing unfunded cancer drugs

2016 ◽  
Vol 24 (1) ◽  
pp. 18-21 ◽  
Author(s):  
Victoria Kletas ◽  
Mario de Lemos
Keyword(s):  
Drug Information ◽  
Public Funding ◽  
Pharmaceutical Companies ◽  
Care Organization ◽  
Publicly Funded ◽  
Cancer Drugs ◽  
Assistance Program ◽  
Assistance Programs ◽  
Patient Assistance ◽  
Set Up

Background New oncology drugs usually become commercially available several months before the funding decisions are made by provincial public payers. Increasingly, patient assistance programs are being set up by pharmaceutical companies in order to facilitate access of their new cancer drugs before public funding decisions are finalized. We discovered that there is a need to keep this information up to date and available in a central repository, thus we have created a centralized patient assistance chart for use by all who require information on accessing unfunded drugs in our province. Methodology The project was carried out at a publicly funded provincial cancer care organization that oversees parenteral and oral chemotherapy treatments across our province. The drug information pharmacist at this organization developed a method of scoping information on upcoming therapies by reviewing a series of recommendations made by various organizations that review oncology treatments. A standard process was developed for including information on the patient assistance chart that is available on the organizations website. Results As of May 2016, the repository contains information on 47 patient assistance programs involving 24 unfunded antineoplastic drugs for various indications. This compared to (7) when it was maintained by a single centre in 2004 and 10 when the process was first centralized in 2009. Conclusion The benefit of patient assistance program availability allows patients to access medications when provincial funding is not available. A standardized approach and methodology to evaluating information was established by our drug information pharmacist; thus allowing for a consistent approach to dissemination of information on assessing unfunded cancer drugs in our province.

Does the Diabetes Health Plan Have a Differential Impact on Medication Adherence Among Beneficiaries with Fewer Financial Resources?

2021 ◽  
Author(s):  
Huang ◽  
MS Norman Turk ◽  
Susan L. Ettner ◽  
Mangione ◽  
Moin ◽  
...  
Keyword(s):  
Medication Adherence ◽  
Propensity Score ◽  
Health Plan ◽  
Low Income ◽  
Income Group ◽  
Differential Impact ◽  
Individual Level ◽  
A Value ◽  
Quasi Experimental ◽  
The Impact

Abstract Background: The Diabetes Health Plan (DHP), a value-based insurance plan that reduces cost sharing, was previously shown to modestly increase employer-level medication adherence. However, it is unclear whether the DHP has a larger impact on individual-level medication adherence among lower- or higher-income beneficiaries. Methods: An employer-level propensity score match was done to identify suitable control employers, followed by individual-level propensity score weighting. These weights were applied to difference-in-difference (DID) models examining 1) the effect of the DHP and 2) the effect of income on changes in adherence to metformin, statins, and ACE/ARBs. The weights were then applied to a differences-in-differences-in-differences (DDD) model to estimate the differential impact of DHP status on changes in adherence by income group. This is a retrospective, quasi-experimental study.Results: There were no significant differences in changes to adherence for any medications between beneficiaries enrolled in the DHP versus standard plans. However, changes in adherence were higher for all medications among those in the highest income strata (>$75,000) versus those in the lowest income strata (<$50,000; p < 0.01). Finally, the DDD term examining the impact of income on the DHP effect was not significant for any comparisons. Conclusion: We did not find significant associations between the DHP and changes in individual-level medication adherence, even for low-income beneficiaries. New strategies to improve consumer engagement may be needed in order to translate value-based insurance designs into changes in patient behavior.

Sign in / Sign up

Export Citation Format

Share Document